Olmesartan Medoxomil E Idroclorotiazide Hcs (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil E Idroclorotiazide Hcs, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in adults who require additional blood pressure control beyond monotherapy. GNH USA supplies Olmesartan Medoxomil E Idroclorotiazide Hcs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomil E Idroclorotiazide Hcs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxomil/hydrochlorothiazide is indicated for management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway. - Hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk. - Hypertensive patients with fluid retention: adds diuretic effect to improve blood pressure control. - Resistant hypertension: provides combined ARB and thiazide action when single‑agent therapy is insufficient.

Olmesartan medoxomil/hydrochlorothiazide may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue. - Increased urination. - Electrolyte disturbances (e.g., low potassium). - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury. - Hyperkalemia or severe electrolyte imbalance. - Angio‑edema. - Liver function abnormalities. - Blood dyscrasias such as agranulocytosis.

When prescribing Olmesartan medoxomil/hydrochlorothiazide, clinicians should consider several safety aspects. - Pregnancy: contraindicated due to risk of fetal toxicity; avoid in all trimesters. - Renal impairment: monitor kidney function and adjust therapy as needed. - Electrolyte balance: check serum potassium and sodium regularly. - Concomitant NSAIDs: may reduce antihypertensive effect and affect renal function. - Gout: thiazide component can increase serum uric acid; monitor patients with a history of gout. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Olmesartan medoxomil/hydrochlorothiazide interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels and potential toxicity. - ACE inhibitors or other ARBs: additive hypotensive effect and renal risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt blood‑pressure reduction and affect renal function. - Antidiabetic agents: diuretic‑induced hypokalemia can modify glucose control. - Antimicrobials such as trimethoprim‑sulfamethoxazole: may increase risk of hyperkalemia.